Supplemental Table of Contents

Table S1 – Inclusion and Exclusion Criteria for the Systematic Review	1
Figure S1 – Schema of Literature Search	2
Figure S2 – Bias Assessment for Randomized Control Trials	3
Table S2 – Cochrane Risk of Bias for Randomized Control Trails	4
Figure S3 – Bias Assessment for Observational Studies	5
Table S3 – Newcastle-Ottawa Risk of Bias for Observational Studies	6
Figure S4 – Funnel Plot of Reported Outcomes	7
Table S4 - Confounding Factors Affecting Bone Mineral Density 8	3-10

Question Component	Inclusion Criteria	Exclusion Criteria
Population	 Adult patients (> 18 years) Renal transplant (deceased or living donor kidney transplantation) Outcome data available > 1 year post-renal transplantation 	• Patients with other organ transplants, including kidney-pancreas transplantation
Intervention	• Use of any bisphosphonate (oral or IV) post- renal transplant, alone or in combination with other agents (calcium, vitamin D, etc.)	
Outcomes	 Primary: Change in BMD from baseline Secondary: Fracture incidence Other confounding variables (i.e. immunosuppression, BMI, smoking) 	• Trials that did not provide information either on BMD or fracture incidence
Study Design	 Randomized trials Observational studies (cohort, case-control) 	 Case series Case reports Review articles (systematic, meta-analysis, descriptive)

$Table \ S1-Inclusion \ and \ Exclusion \ Criteria \ for \ the \ Systematic \ Review$

Figure S1 – Sample Search Strategy – Ovid MEDLINE 2016

LINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present		
# Searches	Results	Туре
	(E224)	9 2020 000
	1000	9 TO THE PARTY IN THE PARTY INTERPARTY IN THE PARTY INTE PARTY I
	16236	9 TO THE PARTY IN THE PARTY INTERPARTY IN THE PARTY INTE PARTY I
III Yaadharysaktaan jaadhaa dh	0	9 TO THE PARTY IN THE PARTY INTERPARTY IN THE PARTY INTE PARTY I
	20	9 TO THE PARTY IN THE PARTY INTERPARTY IN THE PARTY INTE PARTY I
i dipensir dengidasi	(Case)	9 TO THE PARTY IN THE PARTY INTERPARTY IN THE PARTY INTE PARTY I
\$\$ (I) DU(((((()))))	ngse	9 TO THE PARTY IN THE PARTY INTERPARTY IN THE PARTY INTE PARTY I
~~ (II) DEN(II) III (III)	2000	9 202000000
»))III/ARIQUE ()	220	5 TO THE PARTY IS A PA
	Itsijjse	5 TO THE PARTY IS A PA
	80222	5 TO THE PARTY IS A PA
	Satera	5 TO THE PARTY IS A PA
	2006	9 2020 000
	Sidke	5 TO THE PARTY IS A PA
™ topet man_man_	IIE-00	s analika
	814660	5 TO THE PARTY IS A PA
		5 TO THE PARTY IS A PA
29 (failed)	\$81.42°	5 TO THE PARTY IS A PA
te destal	E GARE III-'O	s analika
	14142-011	9 2020 000
	Ingg II Co	9 202000000
וו ביבה בה בקורה בני באנהילים «בחילים»	20059F	9 2020 000
₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩	nne je	9 2020 000
	2980000	s analika
	21631e	9 202000000
3. Opera decaración pocamentas) essis astycas en provinción de constructiva de construcción de Construcción de construcción de construcció	D-4	9 Tran ilife
Mail CHIPATORIA COMPANYA CONFERENCIAL CONFERENCIAL CONFERENCE C	1820	9 2020 Mitz
() INTERPORT #CONTRACTOR (INTERPORT PROVIDED AND A CONTRACTOR (INTERPORT) A CONTRACTOR (INTERPORT PROVIDED A CONTRACTOR A CONTRACT A CONTRACTOR A	lilling:	s example
 • EBERTRATING AND INFORMATION (BERTRATING AND AND AND AND AND AND AND AND AND AND	11220a	9 a an ann an
CONVERSION CONDENSATIVE SUBJECTIVE AND	h'fhe	9 20 2 010
CERTICAL DEPENDING CONTRACTOR CONTRA CONTRACTOR CONTRACTOR CONT	22	1 transfer
III CHIEDEKSIC ADESMANKASY STUKATIVASHANKANCONLOV 40 40000, CERK-40000, CERK-40000, CERK-40000, CERK-40000, CHIESANY CERKENTSID 4000000000000000000000000000000000000	25601	9 Tranili
10000000000000000000000000000000000000	211	9 ada niji fa
() +CU(EUX-630-6-CEAH44(22) +CU(EUX)000(C++CEAE04(2-4) +CO+(CH4C+4))+FCH230(2-4))+CEAE40(2-4) -T(CAH4)+CEAE70(2-4)(-+CCH4))+FCH23(0-0(CH4)+CEAE70(2-4))+FCH23(0-0(CH4)+CEAE70(2-4))+CEAE70(2-4))+FCH23(0-0(CH4)+FCH23(0-0(CH4)+CEAE70(0-0(0-0(CH4)+CEAE70(0-0(CH4)+CEAE70(9 comulte
E SEMENTERIO CONTRACTOR DI LO DEL CONTRACTORI DI ACCONTRACTORI DI CONTRACTORI	~@	9 teternilite
ון און מאון מאג מאגמאלמוי גמול באליבאווי באון מאון בא	111916	9 2013 000

	Selection E	Bias	Performance Bias	Detection Bias	Attrition Bias	Reporting Bias	Other Bias
	Random Sequence Generation	Allocation Concealment	Participants and Personnel Blinding	Blinding of Outcome Assessment	Incomplete Outcome Data	Selective Reporting	Other Bias
Sánchez- Escuredo, 2015	•		•	-	+	+	-
Okamoto, 2014	•		•		+	+	•
Walsh, 2009	•	+	+	+	+	+	?
Lan, 2008	•		•	•	?	•	•
Schwarz, 2004	•		+	+	+	+	•
Fan, 2003	•		-		+	+	?
Jeffery, 2003	?	?	-	•	+	?	•
Кос, 2002			•	•	+	?	•

Figure S2 – Bias Assessment for Randomized Control Trials using the Cochrane Risk of Bias Tool Criteria [27]

Cochrane Risk of Bias Tool Criteria								
	Select	ion Bias	Performance Bias	Detection Bias	Attrition Bias	Reporting Bias	Other Bias	Total
Study	Random Sequence Generation	Allocation Concealment	Blinding of Participants & Personnel	Blinding of Outcome Assessment	Incomplete Outcome Data	Selective Reporting	Other Sources of Bias	
Sánchez- Escuredo, et al. 2015	0	0	0	0	2	2	0	4
Okamoto, et al. 2014	0	0	0	0	2	2	0	4
Walsh, et al. 2009	2	2	2	2	2	2	1	13
Lan, et al. 2008	0	0	0	0	1	0	0	1
Schwartz, et al. 2004	0	0	2	2	2	2	0	8
Fan, et al. 2003	0	0	0	0	2	2	1	5
Jeffrey, et al. 2003	1	1	0	0	2	1	0	5
Koc, et al. 2002	0	0	0	0	2	1	0	3

Table S2 – Cochrane Risk of Bias Table for RCTs

0 = high risk1 = unclear

2 = low risk

		Selection	Comparability	Outcome Reporting
studies	Arlen, 2001	+	+	+
Case-Control Studies	Huang, 2012		?	Ŧ
Case-C	Tillman, 2016	+	?	+
	Cruz, 2002	+	+	+
lies	Ahn, 2006	-	+	+
Cohort Studies	Conley, 2008	+	+	+
Cohc	Yamamoto, 2013	-	+	+
	Naylor, 2014		+	+

Figure S3 – Risk of Bias Graph for Observational Studies using the Newcastle-Ottawa Criteria [28]

	Newcastle-Ottaw	a Criteria Case-Contro	ol Studies	
	Selection (/1)	Comparability of Cohorts (/2)	Outcome (/1)	TOTAL SCORE
Study	 Cases and controls clearly defined Representativene ss of sample 	 Demographic characteristics Potential confounding factors 	 Ascertainment of exposure Non-response rate 	(/4)
Arlen, 2001	1	2	1	4
Huang, 2012	0	1	1	2
Tillman, 2016	1	1	1	3

Table S3 – Newcastle-Ottawa Risk of Bias Table for Observational Studies	Table S3 – Newcastle-Ottav	a Risk of Bias Table for	or Observational Studies
--	----------------------------	--------------------------	--------------------------

	Newcastle-Ottawa Criteria Cohort Studies						
	Selection (/1)	Comparability of Cohorts (/2)	Outcome (/1)	TOTAL SCORE			
Study	 Ascertainment of exposure Representativeness of exposed and unexposed cohorts Outcome not present at study start 	 Demographic characteristics Potential confounding factors 	 Assessment method Blinding Follow-up length Losses to follow- up accounted for 	(/4)			
Cruz, 2002	1	2	1	4			
Ahn, 2006	0	2	1	3			
Conley, 2008	1	2	1	4			
Yamamoto, 2013	0	2	1	3			
Naylor, 2014	0	2	1	3			




Figure S4 – Funnel Plot of Reported Outcomes

Table S3 - Confounding Factors Affecting Bone Mineral Density in Post RenalTransplant Patients Between Bisphosphonate And Control Groups

S teroid Use	Description	Findings
Jeffery, et al. (2003) [37]	 From baseline (n=211): Cumulative prednisone dose = 43.0±35.8g 	 Prednisone correlated with decreased BMD at femur (univariate, p<0.001) Prednisone was an independent predictor of low BMD (multivariate, p<0.01)
Ahn, et al. (2006) [44]	 Mean change in T-score (spine) over first year post-transplant: Double IS regimen (CsA, tacrolimus, steroid)-0.57±0.70 (p = 0.26) Triple IS regimen (CsA, tacrolimus, steroid and my cophenolate mofetil): -0.46±0.66 (p = 0.26) 	No significant difference in change in BMD over first year post-transplant based on IS regimens including steroid
Huang, et al. (2012) [42]	 Patients stratified based on baseline bone health into 3 groups: normal/osteopenic/osteoporotic. The osteoporotic group was treated with Fosamax Osteoporotic group received a greater cumulative steroid dose than the osteopenic group (1326.5 mg vs. 724.5 mg; p<0.01) 	Increase in lumbar spine BMD greater in the osteoporotic group than osteopenic group (0.033 g/cm ² vs. 0.009 g/cm ² ; p<0.05)
	 To detect a difference in BMD at follow-up due to the use of IS agents, patients were divided into osteoporotic vs. non-osteoporotic based on their 1st follow-up BMD results. Cumulative dose of prednisolone in non-osteoporotic/osteoporotic: 872±730mg/1326.5±961mg (p<0.01) 	Prednisolone showed a positive association in patients with osteoporosis at follow-up BMD (univariate, OR 5.18; 95% CI 1.6–16.4, p<0.01)
Naylor, et al. (2014) [40]	 β for glucocorticoid exposure in predictors of BMD model: between no previous osteoporosis/previous osteoporosis groups: L-spine: -0.008 (p=0.22)/-0.001 (p=0.82) Total hip: -0.010 (p=0.08)/0.005 (p=0.28) Femoral neck: -0.004 (p=0.56)/0.010 (p=0.09) 	Greater glucocorticoid exposure was not associated with significant change in BMD, regardless of prior osteoporosis treatment status (p>0.05)
Cyclosporine Use	Description	Findings
Ahn, et al. (2006) [44]	Mean change in T-score spine over first year post- transplant: (Cyclosporine /tacrolimus) -0.51±0.64/- 0.41±0.76 (p=0.24)	No significant difference in change in BMD over first year post-transplant based on cyclosporine use
Huang, et al. (2012) [42]	Cyclosporine use (in 100 mg tablets) between osteoporotic and osteopenic groups 119.20±210.85/ 131.12±177.79 (p>0.05)	No significant difference in change in BMD between osteoporotic and osteopenic groups based on cyclosporine use at 1 year follow-up.
Gender	Description	Findings
Jeffery, et al. (2003) [37]	From baseline (n=211): (Male/female = $149/62$)	Female gender correlated with decreased overall BMD (univariate, p<0.05)
Ahn, et al. (2006) [44]	Mean change in T-score spine over first year post- transplant: • Male/female: -0.49±0.67/-0.47±0.66 (p=0.83)	Mean femoral T-score lower among female recipients (p<0.001). However gender did not influence change in BMD

		overall in first year post-transplant
		(p=0.83)
Tillmann, et al. (2016) [39]	Control: Males: LS: 4.5±7.8 %; FN: 1.7±10.7% Females: LS: 5.3±8.2%; FN: 5.8±14.7% Mann-Whitney U:LS: p = 0.94; FN: p = 0.56	No gender-specific effect on BMD (p>0.05)
	Ibandronate: • Males: LS: 7.2±6.8%; FN: 3.0±9.8% • Females: LS: 5.8±8.9%; FN: 6.4±15.1% Mann-Whitney U:LS: p = 0.60; FN: p = 0.70	No gender-specific effects on BMD (p>0.05)
Huang, et al. (2012) [42]	Overall BMD difference values were not different (p>0.05)	No significant gender-related differences in bone turnover during 14-month period of mean follow-up (p>0.05).
	Fosamax increased the BMD at the lumbar spine and the hip in males ($p<0.05$), but only at the lumbar spine in females ($p<0.05$).	Sites of action of Fosamax differ between genders
Naylor, et al. (2014) [40]	 β for male gender in predictors of BMD model: between no previous osteoporosis/previous osteoporosis groups: L-spine: 0.003 (p=0.46)/0.008 (p<0.01)* Total hip: 0.002 (p=0.53)/0.002 (p=0.38) Femoral neck: 0.005 (p=0.08)/-0.002 (p=0.55) 	No overall clinically significant gender- related differences in BMD
BMI (kg/m ²)	Description	Findings
Jeffery, et al. (2003) [37]	Raw baseline data from patients not provided	Low body weight ($p<0.001$) and low BMI ($p<0.01$) correlated with reduced lumbar and femoral BMD (univariate)
Ahn, et al. (2006) [44]	Mean change in T-score spine over first year post- transplant: • <18.5 = -0.5±0.67 • 18.5 - 24.9 = -0.5±0.67 • ≥25 = -0.34±0.60	Spine and femoral T-scores lower in patients with lower BMI. However BMI did not influence change in BMD in first year post-transplant (p=0.40)
Naylor, et al. (2014) [40]	β for baseline BMI in predictors of BMD model: between no previous osteoporosis/previous osteoporosis groups: L-spine: 0.0001 (p=0.95)/-0.000007 (p=1.0) Total hip: 0.0005 (p=0.70)/-0.0004 (p=0.71) Femoral neck: 0.0004 (p=0.76)/-0.001 (p=0.36) β for change in BMI across scans in predictors of BMD model: between no previous osteoporosis/previous osteoporosis groups: L-spine: 0.000 (p=0.88)/0.001 (p=0.28) Total hip: 0.002 (p<0.05)*/0.00007 (p=0.84)	Greater increases in BMI in the no prior osteoporosis treatment group were associated with significant increase in BMD at total hip and femoral neck (p<0.05)
Diabetes	Description	Findings
Jeffery, et al. (2003) [37]	 From baseline participant characteristics (n=211): Pre-transplant diabetes = 29/211 	 Pre-transplant diabetes correlated with decreased BMD (univariate, p<0.001) Pre-transplant diabetes was an independent predictor of low BMD (multivariate, p<0.001)

Ahn, et al. (2006) [44] Huang, et al. (2012) [42]	Mean change in T-score spine over first year post- transplant: • No DM/DM:-0.52±0.67/-0.15±0.50 (p<0.01) N=12/76 were diabetic (osteoporotic=5, non- osteoporotic=7)	Low BMD significantly correlated with being in non-diabetes group ($p<0.01$) Binary logistic regression did not identify DM as significant factor in BMD (OR = ~0.6)
HD Duration	Description	Findings
Ahn, et al. (2006) [44]	 Mean change in T-score spine over first year post-transplant: HD <12 months: -0.39±0.57 (p=0.001) HD ≥12 months: -0.67±0.79 	Low BMD significantly correlated to longer period (≥12 months) of HD pre- transplant (p=0.001)
Smoking	Description	Findings
Huang, et al. (2012) [42]	N=10/76 were smokers (all male); 5 had normal baseline BMD, 5 had osteoporosis at baseline BMD	Binary logistic regression did not identify smoking as significant factor in BMD (OR = ~0.8)

Abbreviations:

BMD-Bone Mineral Density CsA – Cyclosporine LS lumbar spine HD – Hemodialysis IS - immunosuppression FN – femoral neck